Stryker (NYSE:SYK) Price Target Cut to $390.00 by Analysts at Citizens Jmp

Stryker (NYSE:SYK) had its target price lowered by stock analysts at Citizens Jmp from $400.00 to $390.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “market outperform” rating on the medical technology company’s stock. Citizens Jmp‘s target price suggests a potential upside of 25.36% from the stock’s previous close.

Other analysts have also issued research reports about the company. BMO Capital Markets restated an “outperform” rating and set a $317.00 price target on shares of Stryker in a report on Wednesday, September 9th. Truist Financial cut their price objective on shares of Stryker from $340.00 to $310.00 and set a “hold” rating on the stock in a report on Tuesday, October 6th. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Sanford C. Bernstein restated a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. Finally, UBS Group initiated coverage on Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $362.36.

Stryker Stock Up 2.3%

NYSE SYK opened at $311.12 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock has a market capitalization of $119.34 billion, a PE ratio of 32.24, a PEG ratio of 1.96 and a beta of 0.78. The business’s 50-day moving average is $293.56 and its 200 day moving average is $324.86. Stryker has a 1 year low of $267.00 and a 1 year high of $389.33.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.19 earnings per share. Sell-side analysts forecast that Stryker will post 14.93 earnings per share for the current year.

Insider Transactions at Stryker

In other Stryker news, Director Ronda Stryker sold 50,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 in the last three months. 4.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. State Street Corp grew its position in shares of Stryker by 1.2% in the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock valued at $4,903,772,000 after purchasing an additional 183,400 shares during the period. Wellington Management Group LLP increased its holdings in shares of Stryker by 0.6% during the second quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after buying an additional 45,478 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Stryker in the second quarter worth $1,404,284,000. Royal Bank of Canada raised its stake in Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after buying an additional 199,863 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Stryker by 21.8% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after acquiring an additional 481,175 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Third-quarter revenue increased approximately 7.6%–7.7% year over year to $6.52 billion, while adjusted EPS rose to $3.52 from $3.19 a year earlier. Stryker reports third quarter 2026 operating results
• Neutral Sentiment: Management is navigating manufacturing constraints in the vascular business and lingering operational effects from the cybersecurity incident disclosed in March. A new CEO is also taking over as the company reassesses its growth trajectory, making the 2027 starting point a key investor focus. Stryker’s Guidance Cut Rattles Investors
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 missed the roughly $3.55–$3.56 analyst consensus, and revenue of $6.52 billion fell short of the $6.62 billion estimate. The earnings and sales misses triggered a significant selloff. Stryker Q3 2026 earnings revenue and EPS miss
• Negative Sentiment: Stryker lowered its 2026 organic net sales growth forecast to 6.5%–7.0% from 8.3%–9.3%, while adjusted EPS guidance moved to $14.80–$14.90 from $14.95–$15.10. The larger sales reduction suggests demand, supply, or execution concerns beyond a one-quarter earnings miss. Stryker Slides After Lowering 2026 Outlook
• Negative Sentiment: Analysts subsequently cut their forecasts and price targets, reinforcing concerns about slower growth, margin pressure, and the company’s ability to regain momentum in 2027. Stryker Analysts Cut Their Forecasts

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.